ÍøºìºÚÁÏ

Skip to main content

Jorge E Lascano, MD

Critical Care Specialist

Photo of Jorge E Lascano

Research at a glance

Top areas of exploration

  • alpha 1-Antitrypsin Deficiency , 9 publications
  • Pulmonary Disease, Chronic Obstructive , 8 publications
  • alpha 1-Antitrypsin , 7 publications
  • Cystic Fibrosis , 3 publications

Research activity

44 publications

427 citations

Why is this important?

Active clinical trials

INBRX101-201

Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 80 Years
Sexes
All
Grifols GC2008

The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in…

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 80 Years
Sexes
All

My publications

44 publications

2023

Impact of a Computerized Clinical Decision Support System to Improve Chronic Obstructive Pulmonary Disease Diagnosis and Testing for Alpha-1 Antitrypsin Deficiency.

Annals of the American Thoracic Society

•

2023

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

•

2023

Lung Inflammation in alpha-1-antitrypsin deficient individuals with normal lung function.

Respiratory research

•

2023

Lung microhaemorrhage drives oxidative/inflammatory damage in α1-antitrypsin deficiency.

ERJ open research

•

2023

Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency.

The American journal of medicine

•